πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 173 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12414983

CD200AR ligands for cancer immunotherapy

Regents of the University of Minnesota Β· Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12384830

Compositions and methods for improving immunotherapy

Regents of the University of Minnesota Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12350322

Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunothera

United Biomedical, Inc. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12338459

DNA-chimeric antigen receptor T cells for immunotherapy

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12329816

Immunotherapy with metabolic enzyme expression

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12325854

Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

Editas Medicine, Inc. Β· Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12311030

Antibody-sting agonist conjugates and their use in immunotherapy

The Board of Regents of the University of Texas System Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12303551

Cellular immunotherapy compositions and uses thereof

Cero Therapeutics Holdings, Inc. Β· Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297509

Biomarkers for predicting tumor response to and toxicity of immunotherapy

MIRA DX, INC. Β· Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280140

Processes for production of tumor infiltrating lymphocytes and uses of the same in immunot

Iovance Biotherapeutics, Inc. Β· Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12275955

Combining iPSC derived effector cell types for immunotherapy use

Fate Therapeutics, Inc. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12233103

Indoleamine 2,3-dioxygenase based immunotherapy

IO Biotech ApS Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12230364

Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burde

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12230378

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12230379

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12228582

Method and apparatus for testing near infrared-photoimmunotherapy treatment

The United States of America as Represented By The Secretary of the Department of Health and Human Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226434

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12194061

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186428

Combination taxoid nanoemulsion with immunotherapy in cancer

Northwestern University Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178787

T cell receptors for immunotherapy

The Board of Regents of the University of Texas System Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12170134

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12159700

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121541

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12110334

Neutralizing antibodies to the Ξ±vΞ²8 integrin complex for immunotherapy

The Regents of the University of California Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted